Literature DB >> 11433388

A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells.

P Chaux1, B Lethé, J Van Snick, J Corthals, E S Schultz, C L Cambiaso, T Boon, P van der Bruggen.   

Abstract

Antigens encoded by MAGE genes and recognized by T cells are of interest for cancer immunotherapy because of their strict tumoral specificity and because they are shared by many tumors. Several MAGE-1 peptide that are recognized by CD8(+) cytolytic T lymphocytes have been used in therapeutic vaccination trials. To obtain anti-tumor immune response, vaccines combining peptides recognized by CD8(+) and peptides recognized by CD4(+) T cells might be optimal. We focused therefore on the identification of MAGE peptides recognized by CD4(+) T cells. We report here the identification of MAGE-1 epitope EYVIKVSARVRF, which is presented to CD4(+) T lymphocytes by HLA-DR15. This HLA allele is present in 29 % of Asians and 17 % of Caucasians.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433388     DOI: 10.1002/1521-4141(200106)31:6<1910::aid-immu1910>3.0.co;2-k

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.

Authors:  Maria R Parkhurst; John P Riley; Paul F Robbins; Steven A Rosenberg
Journal:  J Immunother       Date:  2004 Mar-Apr       Impact factor: 4.456

Review 2.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.